GSK Poaches New Vaccines R&D Chief From Pfizer

Looking To Close Gap On mRNA Leaders

Phil Dormitzer has been headhunted to help GSK get up to speed in RNA and other vaccine platforms.

GSK vaccines — GSK's vaccines division earned £7bn ($9.31bn) last year, but is facing competition, not least from Pfizer/BioNTech and Moderna's mRNA breakthrough. • Source: Alamy

GlaxoSmithKline has poached a key COVID-19 vaccine research leader from Pfizer to help it stay competitive in the field and catch up with the mRNA leaders.

Phil Dormitzer has been appointed by the UK-headquartered company to be its new global head of vaccines R&D, leaving his...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Stock Watch: Pharma Financial Forecasts Cannot Withstand Headwinds Forever

15 Jul 2025

• By Andy Smith

Pharma company financial guidance emerged largely unscathed from a first quarter punctured by a weakening US dollar and threats of import tariffs on drugs. With other pressures either already evident or on the horizon, guidance revisions may be unavoidable.

Q2 Korea Biotech Roundup: Licensing Deals End, Trials Progress, IPOs Recover

15 Jul 2025

• By Jung Won Shin

Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

14 Jul 2025

• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

14 Jul 2025

• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Takeda Prepares Ground For Oveporexton In Narcolepsy

14 Jul 2025

• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.